Traded Dec 15, 2025 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Traded Nov 17, 2025 · Filed Nov 19, 2025
United Therapeutics's PRESIDENT AND COO sold $3.7M of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$3,704,665
Shares × reported transaction price
19 days after results of Oct 29, 2025, 100 days before results of Feb 25, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +2.5% | +2.6% | −0.1% |
| 30 days | +8.5% | +2.7% | +5.8% |
| 90 days | +1.2% | +3.0% | −1.8% |
| 180 days | +19.0% | +11.5% | +7.5% |
Past results only. Not a forecast.
Traded Dec 15, 2025 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
James Edgemond (CFO AND TREASURER) sold ~$79K of United Therapeutics
Scheduled in advanceJames Edgemond (CFO AND TREASURER) sold ~$414K of United Therapeutics
Scheduled in advance